ADAM28 overexpression regulated via the PI3K/Akt pathway is associated with relapse in de novo adult B-cell acute lymphoblastic leukemia
详细信息 查看全文
- 作者：Xiao-Hui Zhang ; 1 ; zhangxh100@sina.com" class="auth_mail" title="E-mail the corresponding author ; Chen-Cong Wang1 ; Qian Jiang ; Shen-Miao Yang ; Hao Jiang ; Jin Lu ; Qian-Ming Wang ; Fei-Er Feng ; Xiao-Lu Zhu ; Ting Zhao ; Xiao-Jun Huang
- 关键词：B-ALL ; B-cell acute lymphoblastic leukemia ; ATO ; arsenic trioxide ; ADAMA ; disintegrin and metalloproteinases ; RFS ; relapse-free survival ; EFS ; event-free survival ; OS ; overall survival ; CR ; complete remission ; CNS ; central nervous system ; ATRA ; all-trans retinoic acid ; MRD ; minimal residual disease ; BM ; bone marrow ; ELISA ; enzyme-linked immunosorbent assay ; RT-PCR ; real-time quantitative polymerase chain reaction ; ROC ; receiver operating characteristics
- 刊名：Leukemia Research
- 出版年：2015
- 出版时间：November 2015
- 年：2015
- 卷：39
- 期：11
- 页码：1229-1238
- 全文大小：1429 K
文摘
- •
The ADAM28 expression level in relapsed adult B-ALL patients was elevated.
- •
The ADAM28 expression level was associated with EFS in de novo adult B-ALL patients.
- •
Selective inhibitor could inhibit the ADAM28 expression in primary B-ALL cells.
- •
The ADAM28 expression might be regulated via the PI3K/Akt pathway.